KR20060107509A - 헤르페스 감염을 치료하기 위한 방법 및 조성물 - Google Patents

헤르페스 감염을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20060107509A
KR20060107509A KR1020067004565A KR20067004565A KR20060107509A KR 20060107509 A KR20060107509 A KR 20060107509A KR 1020067004565 A KR1020067004565 A KR 1020067004565A KR 20067004565 A KR20067004565 A KR 20067004565A KR 20060107509 A KR20060107509 A KR 20060107509A
Authority
KR
South Korea
Prior art keywords
herpes
iga
mammal
composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067004565A
Other languages
English (en)
Korean (ko)
Inventor
율리히 베츠
클라우스-페터 랏케
Original Assignee
테일크리스 바이오쎄러퓨틱스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테일크리스 바이오쎄러퓨틱스 아이엔씨. filed Critical 테일크리스 바이오쎄러퓨틱스 아이엔씨.
Publication of KR20060107509A publication Critical patent/KR20060107509A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020067004565A 2003-09-05 2004-09-02 헤르페스 감염을 치료하기 위한 방법 및 조성물 Ceased KR20060107509A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/656,781 US6984492B2 (en) 2003-09-05 2003-09-05 Methods and compositions for treating herpes infections
US10/656,781 2003-09-05

Publications (1)

Publication Number Publication Date
KR20060107509A true KR20060107509A (ko) 2006-10-13

Family

ID=34226428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067004565A Ceased KR20060107509A (ko) 2003-09-05 2004-09-02 헤르페스 감염을 치료하기 위한 방법 및 조성물

Country Status (13)

Country Link
US (3) US6984492B2 (https=)
EP (1) EP1663309A2 (https=)
JP (1) JP2007504268A (https=)
KR (1) KR20060107509A (https=)
CN (1) CN1845756A (https=)
AU (1) AU2004272001A1 (https=)
BR (1) BRPI0414139A (https=)
CA (1) CA2537360A1 (https=)
IL (1) IL173805A0 (https=)
NO (1) NO20061184L (https=)
NZ (1) NZ546303A (https=)
WO (2) WO2005023303A1 (https=)
ZA (1) ZA200602738B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2248825T3 (pl) * 2009-05-04 2013-04-30 Ribovax Biotechnologies Sa Fragmenty przeciwciała wiążące antygen do zastosowania w leczeniu i diagnozowaniu chorób oczu
WO2013023362A1 (zh) * 2011-08-16 2013-02-21 深圳市卫武光明生物制品有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
US10829543B2 (en) 2012-10-29 2020-11-10 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
US10100102B2 (en) 2012-10-29 2018-10-16 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
WO2015134368A2 (en) * 2014-03-03 2015-09-11 Albert Einstein College Of Medicine Of Yeshiva University Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
CN114306596A (zh) * 2014-06-26 2022-04-12 海德堡免疫疗法有限公司 抗hsv抗体的局部应用
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2017083681A1 (en) 2015-11-13 2017-05-18 The University Or North Carolina At Chapel Hill Optimized crosslinkers for trapping a target on a substrate
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2020097528A1 (en) * 2018-11-08 2020-05-14 The Board Of Trustees Of The University Of Illinois Treatment and diagnosis of autoantibody-mediated eye diseases
WO2021207348A1 (en) * 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617379A (en) * 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4665159A (en) * 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4717564A (en) * 1985-11-07 1988-01-05 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
RU2051054C1 (ru) 1992-04-14 1995-12-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Способ получения препарата противогерпетического иммуноглобулина человека
US5681565A (en) * 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
WO1994015640A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
AU6968098A (en) * 1997-04-15 1998-11-11 Advanced Viral Research Corp. Topical treatment of skin diseases and eye afflictions
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies

Also Published As

Publication number Publication date
NZ546303A (en) 2009-03-31
US6984492B2 (en) 2006-01-10
EP1663309A2 (en) 2006-06-07
CA2537360A1 (en) 2005-03-24
BRPI0414139A (pt) 2006-10-31
WO2005025617A3 (en) 2005-05-26
CN1845756A (zh) 2006-10-11
IL173805A0 (en) 2006-07-05
ZA200602738B (en) 2008-06-25
US20060198848A1 (en) 2006-09-07
WO2005025617A2 (en) 2005-03-24
JP2007504268A (ja) 2007-03-01
US20050053605A1 (en) 2005-03-10
AU2004272001A1 (en) 2005-03-24
NO20061184L (no) 2006-06-01
US20090232798A1 (en) 2009-09-17
WO2005023303A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
US20090232798A1 (en) Methods and compositions for treating herpes infections
Tsatsos et al. Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents
AU2016293004B2 (en) Stuffy nose deblocking composition having antiviral activity
CA1057195A (en) Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
BG60544B1 (en) Antiviral and antibacterial preparation and method for its usage
Colin et al. Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir
JP2724711B2 (ja) 医薬品生成物
CA2009505C (en) Inhibitor of herpesvirus adsorption
CN111249288B (zh) 甘露葡萄糖醛酸寡糖及其衍生物在制备治疗和/或预防hcmv药物中的应用
WO2006096937A1 (en) Use of copper silicate for the control of herpes infections
RU2233171C2 (ru) ПОЛИФУНКЦИОНАЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ L-ЛИЗИН-α-ОКСИДАЗЫ ИЗ ГРИБА РОДА TRICHODERMA И СПОСОБ ПОЛУЧЕНИЯ ЭТОГО ФЕРМЕНТА
CN1098687C (zh) 氨基嘌呤抗病毒剂在治疗和预防潜伏性疱疹病毒感染中的用途
US4963577A (en) Use of the thiazole derivative tiprotimod for the preparation of an agent for the therapy of virus infections
MXPA06002585A (en) Methods and compositions for treating herpes infections
KR100771025B1 (ko) 사이토카인 생산 억제제
US5283239A (en) Inhibitor of herpesvirus absorption
CN116672346B (zh) 普拉曲沙在制备治疗vzv所致疾病的药物中的用途
US4230725A (en) Antiviral agent
CN102940686B (zh) 川楝子提取物在制备抗病毒药物中的应用及其提取方法
CN120478413A (zh) 蟾酥及蟾毒灵在制备单纯疱疹病毒抑制剂中的应用
Martin et al. Antiviral activity of a D‐glucosamine derivative against herpetic ulcers (HSV type 2) in rabbit cornea
CN116850189A (zh) 普拉曲沙在制备治疗hsv所致疾病的药物中的用途
WO2021257007A1 (en) An antiviral pharmaceutical composition with therapeutic agent originated from astraeus asiaticus
Nicholson Antiviral Therapy: Respiratory Infections, Genital Herpes, and Herpetic Keratitis
JP2007530412A (ja) アデノウィルス及び関連疾患の、局所投与による抗ウィルス治療法及び予防法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060304

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20060804

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090831

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110721

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120306

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110721

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I